• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

2021 年中国淋球菌临床分离株 penA-60.001 耐药谱特征和基因组分析

Antimicrobial Resistance Profiling and Genome Analysis of the penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021.

机构信息

Department of Pharmacy, the First Affiliated Hospital of Naval Medical University, Shanghai, China.

The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.

出版信息

J Infect Dis. 2023 Sep 15;228(6):792-799. doi: 10.1093/infdis/jiad258.

DOI:10.1093/infdis/jiad258
PMID:37462263
Abstract

BACKGROUND

Neisseria gonorrhoeae antimicrobial resistance (AMR) is an urgent public health threat. With dissemination of FC428-related clones, the efficacy of ceftriaxone has become controversial.

METHODS

Agar dilution and whole genome sequencing were used to analyze AMR.

RESULTS

High resistance to penicillin (75.2%), tetracycline (87.9%), ciprofloxacin (98.3%), ceftriaxone (8.9%), cefixime (14.3%), and azithromycin (8.6%) was observed among 463 isolates first collected in China in 2021. All penA-60.001 clones exhibited resistance to ceftriaxone or cefixime, and 1 of the 12 cases was resistant to azithromycin. ngMAST and ngSTAR of penA-60.001 isolates showed that single-nucleotide polymorphisms in the porB, tbpB, ponA, gyrA, and parC genes were the major causes of different sequence types. MLST-7365 (n = 5) and MLST-1903 (n = 3) were main genotypes, and the other 4 strains featured MLST-10314, MLST-13871, MLST-7827 and MLST-1600. Furthermore, resistance markers (eg, penA, blaTEM-1, blaTEM-135) and virus factors were detected. Most penA-60.001 strains were fully mixed with global FC428-related clones; 2021-A2 and F89 had the same origin; and 2021-A1 exhibited a unique evolutionary trajectory.

CONCLUSIONS

Results provide the first demonstration of extremely severe AMR rates of N gonorrhoeae in China in 2021, particularly strains with ceftriaxone decreased susceptibility. The sustained transmission of penA-60.001 subclones might further threaten treatment effectiveness.

摘要

背景

淋病奈瑟菌的抗菌药物耐药性(AMR)是一个紧迫的公共卫生威胁。随着 FC428 相关克隆的传播,头孢曲松的疗效受到了质疑。

方法

采用琼脂稀释法和全基因组测序分析 AMR。

结果

2021 年首次在中国采集的 463 株分离株中,青霉素(75.2%)、四环素(87.9%)、环丙沙星(98.3%)、头孢曲松(8.9%)、头孢克肟(14.3%)和阿奇霉素(8.6%)的耐药率较高。所有的 penA-60.001 克隆均对头孢曲松或头孢克肟耐药,12 例中有 1 例对阿奇霉素耐药。penA-60.001 分离株的 ngMAST 和 ngSTAR 表明,porB、tbpB、ponA、gyrA 和 parC 基因的单核苷酸多态性是不同序列型的主要原因。MLST-7365(n=5)和 MLST-1903(n=3)是主要基因型,另外 4 株为 MLST-10314、MLST-13871、MLST-7827 和 MLST-1600。此外,还检测到耐药标记(如 penA、blaTEM-1、blaTEM-135)和病毒因子。大多数 penA-60.001 菌株与全球 FC428 相关克隆完全混合;2021-A2 和 F89 具有相同的起源;2021-A1 则表现出独特的进化轨迹。

结论

研究结果首次在中国展示了 2021 年淋病奈瑟菌极高的 AMR 率,尤其是对头孢曲松敏感性降低的菌株。penA-60.001 亚克隆的持续传播可能进一步威胁治疗效果。

相似文献

1
Antimicrobial Resistance Profiling and Genome Analysis of the penA-60.001 Neisseria gonorrhoeae Clinical Isolates in China in 2021.2021 年中国淋球菌临床分离株 penA-60.001 耐药谱特征和基因组分析
J Infect Dis. 2023 Sep 15;228(6):792-799. doi: 10.1093/infdis/jiad258.
2
Dissemination and genome analysis of high-level ceftriaxone-resistant 60.001 strains from the Guangdong Gonococcal antibiotics susceptibility Programme (GD-GASP), 2016-2019.2016-2019 年广东省淋球菌耐药监测项目(GD-GASP)中高水平头孢曲松耐药 60.001 株的传播和基因组分析。
Emerg Microbes Infect. 2022 Dec;11(1):344-350. doi: 10.1080/22221751.2021.2011618.
3
Sustained transmission of the ceftriaxone-resistant Neisseria gonorrhoeae FC428 clone in China.中国耐头孢曲松淋病奈瑟菌 FC428 克隆的持续传播。
J Antimicrob Chemother. 2020 Sep 1;75(9):2499-2502. doi: 10.1093/jac/dkaa196.
4
Emergence and Genomic Characterization of Neisseria gonorrhoeae Isolates with High Levels of Ceftriaxone and Azithromycin Resistance in Guangdong, China, from 2016 to 2019.2016 年至 2019 年期间,中国广东出现了对头孢曲松和阿奇霉素高度耐药的淋病奈瑟菌分离株,并对其进行了基因组特征分析。
Microbiol Spectr. 2022 Dec 21;10(6):e0157022. doi: 10.1128/spectrum.01570-22. Epub 2022 Nov 15.
5
Whole-genome sequence analysis of high-level penicillin-resistant strains and antimicrobial susceptibility of Neisseria gonorrhoeae clinical isolates from Thailand.泰国高水平青霉素耐药淋病奈瑟菌临床分离株的全基因组序列分析及药敏结果
PLoS One. 2022 Jul 29;17(7):e0271657. doi: 10.1371/journal.pone.0271657. eCollection 2022.
6
Antimicrobial resistance and heterogeneity of Neisseria gonorrhoeae isolated from patients attending sexually transmitted infection clinics in Lusaka, Zambia.赞比亚卢萨卡性传播感染门诊分离的淋病奈瑟菌的耐药性和异质性。
BMC Genomics. 2024 Mar 18;25(1):290. doi: 10.1186/s12864-024-10155-y.
7
Markedly Increasing Antibiotic Resistance and Dual Treatment of Neisseria gonorrhoeae Isolates in Guangdong, China, from 2013 to 2020.2013 年至 2020 年期间,中国广东淋病奈瑟菌分离株的抗生素耐药性显著增加和双重治疗。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0229421. doi: 10.1128/aac.02294-21. Epub 2022 Mar 29.
8
penA profile of Neisseria gonorrhoeae in Guangdong, China: Novel penA alleles are related to decreased susceptibility to ceftriaxone or cefixime.中国广东淋病奈瑟菌的 penA 基因特征:新型 penA 等位基因与头孢曲松或头孢克肟的敏感性降低有关。
Int J Antimicrob Agents. 2024 Apr;63(4):107101. doi: 10.1016/j.ijantimicag.2024.107101. Epub 2024 Feb 6.
9
High-level cefixime- and ceftriaxone-resistant Neisseria gonorrhoeae in France: novel penA mosaic allele in a successful international clone causes treatment failure.法国高水平头孢克肟和头孢曲松耐药淋病奈瑟菌:一种成功的国际克隆中的新型 penA 嵌合等位基因导致治疗失败。
Antimicrob Agents Chemother. 2012 Mar;56(3):1273-80. doi: 10.1128/AAC.05760-11. Epub 2011 Dec 12.
10
Increase in Multidrug Resistant FC428-Like Isolates Harboring the Mosaic penA 60.001 Gene, in Nanjing, China (2017-2020).中国南京(2017 - 2020年)携带嵌合型penA 60.001基因的多重耐药FC428样分离株增加。
Infect Drug Resist. 2023 Jun 23;16:4053-4064. doi: 10.2147/IDR.S408896. eCollection 2023.

引用本文的文献

1
Molecular epidemiology of isolates in Russia, 2015-2023: current trends and forecasting.2015 - 2023年俄罗斯分离株的分子流行病学:当前趋势与预测
Front Cell Infect Microbiol. 2025 Feb 19;15:1526859. doi: 10.3389/fcimb.2025.1526859. eCollection 2025.
2
Molecular screening to track ceftriaxone-resistant FC428-like strains' dissemination in four provinces of China, 2019 to 2021.2019年至2021年分子筛查追踪中国四个省份耐头孢曲松的FC428样菌株的传播情况。
Euro Surveill. 2025 Feb;30(6). doi: 10.2807/1560-7917.ES.2025.30.6.2400166.
3
Emerging epidemic of the Africa-type plasmid in penicillinase-producing in Guangdong, China, 2013-2022.
2013 - 2022年中国广东产青霉素酶菌株中非洲型质粒的新出现流行情况
Emerg Microbes Infect. 2025 Dec;14(1):2440489. doi: 10.1080/22221751.2024.2440489. Epub 2024 Dec 26.
4
Emergence and evolution of mosaic and alleles in a core genogroup that was historically susceptible to extended spectrum cephalosporins.在一个历史上对广谱头孢菌素敏感的核心基因组群中,镶嵌体和等位基因的出现与演变。
Front Microbiol. 2024 Oct 1;15:1401303. doi: 10.3389/fmicb.2024.1401303. eCollection 2024.
5
World Health Organization Enhanced Gonococcal Antimicrobial Surveillance Programme, Cambodia, 2023.世界卫生组织强化淋球菌抗菌药物监测项目,柬埔寨,2023 年。
Emerg Infect Dis. 2024 Jul;30(7):1493-1495. doi: 10.3201/eid3007.240354.
6
Managing treatment failure in Neisseria gonorrhoeae infection: current guidelines and future directions.淋病奈瑟菌感染治疗失败的管理:当前指南和未来方向。
Lancet Infect Dis. 2024 Aug;24(8):e532-e538. doi: 10.1016/S1473-3099(24)00001-X. Epub 2024 Feb 14.
7
Two cases of extensively drug-resistant (XDR) infection combining ceftriaxone-resistance and high-level azithromycin resistance, France, November 2022 and May 2023.两例广泛耐药(XDR)感染病例,合并头孢曲松耐药和高水平阿奇霉素耐药,法国,2022 年 11 月和 2023 年 5 月。
Euro Surveill. 2023 Sep;28(37). doi: 10.2807/1560-7917.ES.2023.28.37.2300456.